Traws Pharma, Inc.

Analysis for Ticker: TRAW

Traws Pharma Inc is a clinical stage business that tells people it is making oral medicines for respiratory viruses like influenza and COVID-19 while also researching cancer treatments like narazaciclib and rigosertib. The reality is a mathematical nightmare where the company reported 9,17$ million in income for 2025, but that was just a magic trick using non-cash accounting adjustments. They actually burned 18,18$ million in cash while their bank account dropped from 21,33$ million to just 3,82$ million in twelve months. It is like a child telling their parents they are rich because they found a toy coin, while their actual piggy bank is being emptied through a hole in the bottom. This company is a vessel designed to move money from regular people into the pockets of the people running it, all while drowning in a 639,98$ million accumulated deficit.